4DMedical Raises $57M in Private Placement to Expand AI-Driven Lung Imaging Software

Why It Matters

These advances illustrate how multimodal AI and interoperable digital tools can dramatically improve clinical efficiency, patient safety, and market expansion for health‑tech firms.

Key Takeaways

• Vision AI scribe hits 98% documentation accuracy.
• Multimodal AI reduces pharmacist documentation burden.
• 4DMedical secures $57M, gains EU CE mark for CT:VQ.
• Orchestral's AI tool targets NZ prescription error rates.
• Telstra Health launches FHIR‑based pathology e‑requesting.

Pulse Analysis

The Flinders study underscores a growing trend toward multimodal AI in healthcare, where combining audio and video inputs can dramatically boost the fidelity of clinical documentation. By leveraging smart‑glass hardware and large‑language models like Google Gemini, the system not only captures medication details with near‑perfect accuracy but also integrates real‑time transcript verification, reducing the administrative load on pharmacists and potentially freeing clinicians to focus more on patient interaction.

Meanwhile, 4DMedical’s $57 million capital raise and EU CE certification signal a pivotal shift in pulmonary imaging. Its CT:VQ software creates ventilation‑perfusion maps from routine non‑contrast CT scans, sidestepping the need for radioactive tracers and expensive nuclear equipment. With an estimated 400,000 nuclear VQ scans performed annually in Europe, the technology promises cost savings, faster turnaround, and broader accessibility, positioning the company for rapid commercial rollout across the continent.

In the broader AI‑health ecosystem, Orchestral’s upcoming medication‑safety pilot in New Zealand and Telstra Health’s launch of Smart Connect illustrate how AI and interoperable standards like FHIR are being embedded into everyday clinical workflows. Orchestral’s real‑time prescription‑checking platform aims to curb the high error rates identified in recent pharmacy audits, while Telstra’s e‑requesting tool streamlines pathology orders directly within existing GP software. Together, these initiatives highlight a market moving toward seamless, AI‑driven decision support that enhances safety, reduces friction, and accelerates digital transformation in healthcare.

Deal Summary

Australian medical imaging firm 4DMedical announced it secured AU$83 million (approximately $57 million) in a private placement, supporting the rollout of its AI-powered CT:VQ ventilation-perfusion imaging software in Europe. The funding follows recent CE Mark certification and deployments at major US academic centers, positioning the company for commercial expansion.